NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ZCMD
Zhongchao Inc.
There isn't enough reported data to score ZCMD yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ZCMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ZCMD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ZCMD PE Valuation
ZCMD has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ZCMD Forward outlook
There aren't enough analyst estimates for ZCMD to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ZCMD in the latest year-over-year earnings comparison.
ZCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$178.56 | +$6,300.19 |
| Q2 2024 | -$3,755.71 | +$604.13 |
| Q4 2023 | -$6,478.75 | -$4,797.31 |
| Q2 2023 | -$4,359.84 | -$3,904.65 |
| Q4 2022 | -$1,681.44 | -1301% |
| Q4 2021 | $140.01 | -95% |
| Q4 2020 | $2,723.04 | -2.1% |
ZCMD lost $178.56 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ZCMD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
ZCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.8M | -23% |
| Q2 2025 | $5.6M | -33% |
| Q4 2024 | $7.5M | -17% |
| Q2 2024 | $8.3M | -20% |
| Q4 2023 | $9.1M | +32% |
| Q2 2023 | $10.4M | +42% |
| Q4 2022 | $6.9M | -11% |
| Q2 2022 | $7.3M | -15% |
ZCMD's revenue has slid since its 2020 peak: $6M last quarter, down 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -92% | -12 points |
| Q2 2025 | -16% | +42 points |
| Q4 2024 | -3.9% | +39 points |
| Q2 2024 | -0.6% | -5.8 points |
| Q4 2023 | -80% | -65 points |
| Q2 2023 | -58% | -70 points |
| Q4 2022 | -43% | -70 points |
| Q2 2022 | 5.2% | -24 points |
ZCMD's operating margin was −92% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ZCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$3.2M | -399% |
| Q2 2024 | -$1.3M | +$579.7K |
| Q4 2023 | $1.1M | +$2.5M |
| Q2 2023 | -$1.9M | -$1M |
| Q4 2022 | -$1.5M | -210% |
| Q2 2022 | -$821.9K | -$561.4K |
| Q4 2021 | $1.3M | +$2.5M |
| Q4 2020 | -$1.2M | -1360% |
ZCMD has burned cash in most quarters: −$5M over the past year, against −$1M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ZCMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ZCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +22 shares |
| 1 year | +1.5% | +26 shares |
ZCMD has 1,772 diluted shares, up 1.5% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ZCMD Net Leverage
ZCMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ZCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.0 | Oversold |
| Stochastic | 3.0 | Oversold |
ZCMD's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ZCMD PE vs Healthcare Sector
| Metric | ZCMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ZCMD has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ZCMD on trend strength, trading above more of its moving averages.
ZCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.35 | 31% below |
| 20 week MA | $1.90 | 51% below |
| 50 week MA | $251.7 | 100% below |
| 100 week MA | $981.6 | 100% below |
| 200 week MA | $5,187.8 | 100% below |
ZCMD is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ZCMD on returns for 2026, with the stronger performance.
ZCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58,180.8 | $26,188.8 | -55% |
| 2021 | $26,188.8 | $27,081.6 | +3.4% |
| 2022 | $27,081.6 | $17,260.8 | -36% |
| 2023 | $17,260.8 | $5,224.4 | -70% |
| 2024 | $5,224.4 | $2,455.2 | -53% |
| 2025 | $2,455.2 | $757.4 | -69% |
| 2026 YTD | $757.4 | $0.93 | -100% |
ZCMD has finished four years in a row lower, and it's down 100% so far in 2026.